The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Inclusion Criteria: * Written informed consent * Outpatients of at least 18 years of age * History of GERD-related symptoms of at least 6 months prior to baseline visit * Endoscopically-confirmed GERD or non-erosive GERD Exclusion Criteria: * Zollinger-Ellison syndrome or other gastric hypersecretory condition * Acute peptic ulcer and/or ulcer complications * Pyloric stenosis * Severe or unstable cardiovascular, pulmonary, and/or endocrine disease * Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of reliable contraception in women of child-bearing potential * Intake of any medication for the purpose of eradication of Helicobacter pylori (H. pylori) within the last 28 days prior to study start * Intake of systemic glucocorticoids or non-steroidal anti-inflammatory drugs including cyclooxygenase-2 (COX-2) inhibitors for more than 3 consecutive days within the last 28 days prior to study start; with the exception of acetylsalicylic acid not more than 150 mg per day